Reference
- Novartis AG. News release: Novartis’ Cosentyx is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients. 2017 Nov 30.
Related Articles
Secukinumab Effective Across the Spectrum of Psoriatic Arthritis
A posthoc analysis confirms patients with active psoriatic arthritis (PsA) taking secukinumab experience improvement in all signs and symptoms of PsA as measured by the GRAPPA-OMERACT disease activity core domains.
Study Compares Ixekizumab with Ustekinumab for the Treatment of Nail Psoriasis
In a head-to-head study, ixekizumab was a more effective treatment for nail psoriasis than ustekinumab and resulted in greater skin clearance for patients with plaque psoriasis…
Dermatology Case Answer C: May
C) Tumor necrosis factor (TNF)–α-induced palmoplantar pustular psoriasis
3 Cases of Glomus Tumor—An Unusual Cause of Hand Pain
Hand and digit pain are common presenting symptoms to primary care physicians, rheumatologists, physiatrists and neurologists. There are many causes, but quality and location of the pain can be important clues to the diagnosis. Glomus tumors, neurovascular hamartomas of the glomus body, are an uncommon cause of hand pain. The glomus unit itself is a…